Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

@article{Jackson2008InclusionBM,
  title={Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity},
  author={Carlayne E. Jackson and Richard J. Barohn and Gary S. Gronseth and S. Pandya and Laura L Herbelin},
  journal={Muscle \& Nerve},
  year={2008},
  volume={37}
}
We developed a disease‐specific, 10‐point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high‐dose beta interferon‐1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle… 
View on Wiley
ncbi.nlm.nih.gov
116 Citations
Highly Influential Citations
9
Background Citations
9
Methods Citations
21
Results Citations
1

116 Citations

Citation Type

Citation Type

A cross-sectional study of hand function in inclusion body myositis: Implications for functional rating scale
Development of the sporadic inclusion body myositis physical functioning assessment
TLDR
A PRO tool in alignment with FDA PRO guidance for use in the functional assessment of treatment benefit in sIBM was developed and scored on a 0–10 numerical rating scale.
Optimizing hand-function patient outcome measures for inclusion body myositis
Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease
TLDR
Three patient reported outcomes have been shown to be valid and reliable measures of physical function in GNE myopathy subjects and should be incorporated in investigations to better understand how progressive muscle weakness impacts physical functions in this rare disease population.
Longitudinal observational study investigating outcome measures for clinical trials in inclusion body myositis
TLDR
Moves in muscle strength and physical function in patients with sporadic inclusion body myositis accurately predict disease progression in a reliable and useful way to be used in trial design.
Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials
Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis
TLDR
A pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients found the treatment appeared safe and well tolerated and none of the patients showed a significant clinical improvement.
Demographic and clinical features of inclusion body myositis in north America
TLDR
These data are valuable for informing patients how IBM manifestations are expected to impair daily living and indicate that self‐reporting could be used to establish outcome measures in clinical trials.
A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene
Clinical Scales for the Evaluation of Myopathy Patients
TLDR
This article outlines the process of identifying possible measures for clinical scales in myopathy and detailed consideration has been given to key measures of muscle strength, function, and disability.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 51 REFERENCES
Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis
TLDR
The neurophysiological index (NI), which requires no special technology and no new clinical or technical skills to use, is sensitive to change, and therefore may be useful in clinical trials, as well as in a clinical setting.
Treatment of inclusion-body myositis with IVIg
TLDR
Although the study did not establish efficacy of IVIg, possibly because of the small sample size, the drug induced functionally important improvement in 6 (28%) of the 19 patients, and whether the modest gains noted in certain muscle groups justify the high cost of trying IVIG in IBM patients at a given stage of the disease remains unclear.
Assessment of strength measurements
  • Eric J Sorensen
  • Medicine
    Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
  • 2004
TLDR
A variety of measures have been used in previous clinical trials to measure morbidity and mortality in ALS, but the most proximate means of measuring the extent and progression of disease is to assess muscle strength.
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function
A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis
TLDR
The authors found MMT to be the preferred measure of global strength because of its better Pearson correlation coefficients, essentially equivalent reproducibility, and more favorable coefficient of variation.
A pilot randomized trial of oxandrolone in inclusion body myositis
TLDR
Oxandrolone had a borderline significant effect in improving whole-body strength and a significant effect as measured by MVICT and further study of this drug, possibly in combination with an immunomodulating agent, is warranted.
Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin
TLDR
Intravenous immunoglobulin is the first treatment modality to improve the strength of some muscles in patients with this disabling inflammatory myopathy and the unexpected but encouraging results from this pilot study warrant a controlled trial.
The ALSFRSr predicts survival time in an ALS clinic population
TLDR
In an ALS clinic population, the total Amyotrophic Lateral Sclerosis Functional Rating Scale–revised score at baseline is a strong predictor of death or tracheostomy independently of forced vital capacity and after adjustment for age at baseline, sex, and symptom duration.
A clinical trial of creatine in ALS
TLDR
Any beneficial effect of creatine at 5 g per day in ALS must be small, and other agents should be considered in future studies of therapeutic agents to address mitochondrial dysfunction in ALS.
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
...
1
2
3
4
5
...